Relationship between SARS-CoV-2 antibody titer and the severity of COVID-19

Park, Joung Ha; Jae, Min; Choi, Hyewon; Kim, Min-Chul; Chung, Jin-Won; Lee, Kyu-Sun; Jeong, Dae Gwin; Baek, Moon Seong; Kim, Youn-Jung; Lim, Yaeji; Yoon, Sun Woo; Choi, Seong-Ho

doi:10.1016/j.jmii.2022.04.005

Cited by 18 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is in line with other findings (as reviewed in (Pilz et al, 2022)) on hybrid immunity appearing to be the most protective one. Similarly to the study of Park et al (2022), we found a positive relationship between the severity of COVID-19 symptoms and the antibody levels in recovered unvaccinated subjects.…”

Section: Discussionsupporting

confidence: 83%

Seroprevalence of SARS-CoV-2 antibodies in the county town of Slovakia – a pilot study from the Trencin city

Kajanová¹,

Grossmannova²,

Jelenska³

et al. 2022

View full text Add to dashboard Cite

Slovakia is a country with only 5.45 million inhabitants. However, the past two years of the COVID-19 pandemic have shown huge interregional differences. These were represented by different numbers of diagnosed SARS-CoV-2 cases and the vaccination rates in the regions, as well as by the willingness of the inhabitants to comply with anti-pandemic measures or to undergo testing. The occurrence of such regional disparities provided a rational basis for monitoring the epidemic situation within smaller areas, e.g. at city level.

show abstract

Section: Discussionsupporting

confidence: 83%

Seroprevalence of SARS-CoV-2 antibodies in the county town of Slovakia – a pilot study from the Trencin city

Kajanová¹,

Grossmannova²,

Jelenska³

et al. 2022

View full text Add to dashboard Cite

show abstract

“…This finding also explains why the duration of SARS-CoV-2-specific IgG after vaccination cannot be longer than that of natural immunity. After natural infection, some studies have shown that severe clinical manifestations lead to high titers of anti-SARS-CoV-2 antibodies 45 , 46 , and antibody titers are also affected by sex (with higher titers in men) 7 , 47 . In contrast to these reports, we found that these associations were no longer detectable 2 years after recovery, regardless of prior vaccination.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan

Hong¹,

Nian

et al. 2022

Cell Discov

View full text Add to dashboard Cite

The immunity of patients who recover from coronavirus disease 2019 (COVID-19) could be long lasting but persist at a lower level. Thus, recovered patients still need to be vaccinated to prevent reinfection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or its mutated variants. Here, we report that the inactivated COVID-19 vaccine can stimulate immunity in recovered patients to maintain high levels of anti-receptor-binding domain (RBD) and anti-nucleocapsid protein (NP) antibody titers within 9 months, and high neutralizing activity against the prototype, Delta, and Omicron strains was observed. Nevertheless, the antibody response decreased over time, and the Omicron variant exhibited more pronounced resistance to neutralization than the prototype and Delta strains. Moreover, the intensity of the SARS-CoV-2-specific CD4+ T cell response was also increased in recovered patients who received COVID-19 vaccines. Overall, the repeated antigen exposure provided by inactivated COVID-19 vaccination greatly boosted both the potency and breadth of the humoral and cellular immune responses against SARS-CoV-2, effectively protecting recovered individuals from reinfection by circulating SARS-CoV-2 and its variants.

show abstract

“…They found that, in all patients, titers decreased from 6 to 9 months after the infection, and that titers were higher in those with moderate-severe disease compared to those with mild disease [67] . Although the topic is still debated, some authors speculate that, as high titers of SARS-CoV-2 antibodies correlate with disease severity and mortality, it is possible that the overproduction of antibodies against SARS-CoV-2 induces disease progression via antibody-dependent enhancement, which is well documented for other viral infections [68] , [69] .…”

Section: Overview On Serological Detectionmentioning

confidence: 99%

An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies

Spicuzza¹,

Campagna²,

Maria³

et al. 2023

AIMSMICRO

View full text Add to dashboard Cite

<abstract> <p>Over the last three years, after the outbreak of the COVID-19 pandemic, an unprecedented number of novel diagnostic tests have been developed. Assays to evaluate the immune response to SARS-CoV-2 have been widely considered as part of the control strategy. The lateral flow immunoassay (LFIA), to detect both IgM and IgG against SARS-CoV-2, has been widely studied as a point-of-care (POC) test. Compared to laboratory tests, LFIAs are faster, cheaper and user-friendly, thus available also in areas with low economic resources. Soon after the onset of the pandemic, numerous kits for rapid antibody detection were put on the market with an emergency use authorization. However, since then, scientists have tried to better define the accuracy of these tests and their usefulness in different contexts. In fact, while during the first phase of the pandemic LFIAs for antibody detection were auxiliary to molecular tests for the diagnosis of COVID-19, successively these tests became a tool of seroprevalence surveillance to address infection control policies. When in 2021 a massive vaccination campaign was implemented worldwide, the interest in LFIA reemerged due to the need to establish the extent and the longevity of immunization in the vaccinated population and to establish priorities to guide health policies in low-income countries with limited access to vaccines. Here, we summarize the accuracy, the advantages and limits of LFIAs as POC tests for antibody detection, highlighting the efforts that have been made to improve this technology over the last few years.</p> </abstract>

show abstract

Relationship between SARS-CoV-2 antibody titer and the severity of COVID-19

Cited by 18 publications

References 21 publications

Seroprevalence of SARS-CoV-2 antibodies in the county town of Slovakia – a pilot study from the Trencin city

Seroprevalence of SARS-CoV-2 antibodies in the county town of Slovakia – a pilot study from the Trencin city

COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan

An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies

Contact Info

Product

Resources

About